Trial · Interventional
CompletedPhase 1Registry dataPhase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis
Overview
- Status
- Completed
- Phase
- Phase 1
- Enrollment
- 18 participants (estimated)
- Sponsor
- Stony Brook University · Other
- Design
- Not stated
- Countries
1 country
United States
- Start
- Sept 1998
- Primary completion
- Not stated
- Completion
- Not stated
- First posted
- 19 Oct 1999 (estimated)
- Last update posted
- 4 May 2022
- Conditions
- Sepsis · Respiratory Distress Syndrome · Respiratory Distress Syndrome, Adult
Timeline
1 trial · 1 completed
- Completed
- Ongoing
- Not yet recruiting
- Stopped
- Estimated dates (est.)
- Results posted
- Ph 1
Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis
NCT00004494Start Sept 1998
Registry summary
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
OBJECTIVES: I. Determine the maximum tolerated dose of vasoactive intestinal peptide in patients with acute respiratory distress syndrome. II. Evaluate the safety and pharmacodynamic activity of this peptide in these patients.
Interventions
- vasoactive intestinal peptideDrug
Arms0
The registry lists no arms for this trial.
Primary outcomes0
Outcomes the sponsor listed as primary.
The registry lists no primary outcome.
Posted results
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
No results are posted for this trial.
Completed trials do not always post results.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies0
Studies that cite this trial.
No study cites this trial.
Eligibility
Who could join, as posted.
- Sex
- All
- Age
- from 18 Years
- Healthy volunteers
- Not accepted
Inclusion and exclusion criteria, as posted
PepBank is a research reference. Talk to a doctor before you use any peptide.